AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03458676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Magnetic Resonance Imaging Scan
Description: AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete
Study NCT03458676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care Brain Biopsy and Tumor Removal
Description: During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed.
Study NCT00497458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: testosterone 40 or 80 mg once a day
Study NCT00497458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: testosterone 40 or 80 mg once a day
Study NCT01478529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: iv administration
Study NCT00620451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: gelatin capsule
Study NCT00620451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: gelatin capsule
Study NCT00129402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe with simvastatin
Description: Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
Study NCT00129402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
Study NCT01709721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: Opioid for chronic pain
Study NCT01709721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hydrochloride
Description: Opioid for chronic pain
Study NCT01709721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmable Implantable pump
Description: Programmable Implantable pump delivering intrathecal hydromorphone
Study NCT01709721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Programmable Implantable pump
Description: Programmable Implantable pump delivering intrathecal hydromorphone
Study NCT02876510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine infusion
Study NCT02876510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide infusion
Study NCT02876510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA101 product
Description: i.v. infusion of IMA101 product(s).
Study NCT02876510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-2
Description: Low dose IL-2 Infusion for two weeks
Study NCT02876510 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMADetect
Description: IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
Study NCT02876510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.
Study NCT04614363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: All subjects enrolled in the study will receive a single IV dose of 3-7 mCi of 68 Ga-PSMA (study drug) followed by PET/CT imaging for detection of tumor location.
Study NCT03457896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Patients with HER2 amplified tumors with prior anti-EGFR therapy and/or HER2 mutated colorectal cancer with/or without prior anti-EGFR therapy will receive 4 mg/kg IV loading dose; then 2 mg/kg IV weekly until disease progression. Neratinib: 240 mg taken by mouth daily until disease progression.
Study NCT03457896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Patients with HER2 WT or HER2 amplified with no prior anti-EGFR therapy: 400 mg/m2 IV loading dose; then 250 mg/m2 IV weekly. Neratinib 240 mg taken by mouth daily until disease progression.
Study NCT03457896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: 240 mg taken by mouth daily until disease progression.
Study NCT03457896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Guardant360 Diagnostic Test
Description: Prior to assignment to Arm 1, the Guardant360 diagnostic test will be conducted in blood to confirm known HER2 status for select patients.
Study NCT01825460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Protocol
Description: The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
Study NCT01825460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two manual techniques
Description: The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
Study NCT02675465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB200
Study NCT02675465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT2221
Study NCT01241721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Mammography (PEM)
Description: Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
Study NCT01522222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous, mechanical ventilatory support
Description: Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
Study NCT02309346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
Study NCT02309346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
Study NCT02143804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oncolytic adenovirus expressing GMCSF
Description: Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
Study NCT01245556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
Study NCT01245556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-908662
Description: Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
Study NCT01245556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
Study NCT01245556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
Study NCT05535725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection
Description: on the application of powdered vancomycin in the surgical wound as prophylaxis against the occurrence of surgical site infection at La Paix State University Hospital Haiti over 2 years.Both groups benefited from the same preoperative asepsis protocol. One hour before the incision, 1g of intravenous ceftriaxone is administered to the patients, this dose is maintained during the 48 hours postoperative every 12 hours. At discharged the two groups of patients received oral cloxacilin 500mg three times a day for one week. Patients are dressed every 2 days until the surgical wound has healed. Patients are seen in the outpatient clinic at 2, 4, and 6 weeks, then at one year. We selected 215 patients and retained 204.
Study NCT03846336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Upper extremity function
Description: Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
Study NCT03846336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity function
Description: Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
Study NCT03846336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder position sense
Description: Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
Study NCT03846336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder position sense
Description: Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
Study NCT01207414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
Study NCT01527370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Live
Description: One approximately 0.65 mL injection subcutaneously on Day 1
Study NCT03104127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alter G Bionic Leg
Description: Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
Study NCT03104127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal therapy (physiotherapy)
Description: Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
Study NCT03104127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal therapy (physiotherapy)
Description: Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
Study NCT03216772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus PK Morcellator in PneumoLiner
Description: Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
Study NCT03130738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7-Day Miconazole Oil (Miconazole 2%)
Description: 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
Study NCT03130738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-Day Miconazole Oil (Miconazole 2%)
Description: 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
Study NCT03130738 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 14-Day Placebo - Oil Vehicle
Description: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
Study NCT04298320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 was administered 200mg iv every 2 weeks
Study NCT04298320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN 457
Description: AIN457 was administered 150mg or 300mg ih every 2 weeks
Study NCT04367727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner
Study NCT04367727 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light emitting diode
Description: Light emitting diode at a wavelength of 890 nm is produced by an array of 60 gallium aluminum arsenide light-emitting diodes located on flexible pads and the near infrared photo energy is delivered in a noninvasive, drug-free manner
Study NCT03379181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Patients receive a single dose of 80 mg propranolol p.o.
Study NCT03493997 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy+IAluril®+Ialuril Soft Gels®
Description: Radiotherapy+IAluril®+Ialuril Soft Gels®
Study NCT03493997 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy only
Description: Radiotherapy only
Study NCT00910650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
Description: After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
Study NCT00910650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-myeloablative conditioning chemotherapy
Description: Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
Study NCT00771277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Teams
Description: Use of volunteers organized into teams with a coordinator to provide services to TBI family
Study NCT00423579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin 10/20 mg
Description: 1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
Study NCT00423579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin 40 mg
Description: 1 tablet containing 40 mg of simvastatin per day for 6 weeks
Study NCT01761877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac
Study NCT03013231 — intervention group
Intervention type: BEHAVIORAL
Intervention: Brief Resilience Scale
Description: 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
Study NCT01411345 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Standard Salvage Radiation Treatment (SSRT)
Description: A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
Study NCT01411345 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mapped Tumor Salvage RT (MTSRT)
Description: Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
Study NCT03861897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KRP-NI + KM
Description: Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
Study NCT03861897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KM
Description: Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
Study NCT04162288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Training - Shared Decision Making in Prenatal Screening
Description: TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
Study NCT04162288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Online Training - Online Training on Prenatal Screening
Description: The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules and reports have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
Study NCT03162926 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VC-02 Combination Product (aka PEC-Direct)
Description: PEC-01 cells loaded into a Delivery Device